Compare Novo Nordisk A/S (NVO) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Palantir Technologies Inc — how do they compare? Novo Nordisk A/S trades at $46.23 (market cap $207.85B), while Palantir Technologies Inc trades at $171.92 (market cap $420.39B). The key difference: Palantir Technologies Inc is far larger — about 2× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| NVO | PLTR | |
|---|---|---|
Market Cap | $207.85B | $420.39B |
Sector | Health | Technology |
52-Week High | $63.98 | $207.18 |
52-Week Low | $35.29 | $107.27 |
Enterprise Value | $222.55B | $411.19B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
PLTR trades at $170.50, down 2.68% today but maintains strong momentum with bullish moving averages and recent earnings beats. The company demonstrates exceptional financial performance with 84.8% gross margins and 49% net income margin, though valuation metrics remain elevated with P/E of 149.52. Recent news highlights conflicting institutional views with Cathie Wood selling while analysts maintain buy ratings.
Outlook remains positive with accelerating revenue growth and strong profitability, but high valuations and insider selling present risks. The consensus price target of $213.44 suggests 25% upside potential, though competition and market volatility could pressure the stock near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
